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Objectives: Nunavut is an Arctic territory in Canada subject to many social, economic and health disparities in
comparison to the rest of the nation. The territory is affected by health care provision challenges caused by small,
geographically isolated communities where staffing shortages and weather related access barriers are common
concerns. In addition to national universal healthcare, the majority of the inhabitants of Nunavut (~85 %) are Inuit
beneficiaries of no-charge pharmaceuticals provided through federal and/or territorial budgetary allocations. This
research examines how existing pharmaceutical administration and distribution policies and practices in Nunavut
impact patient care.
Methods: This grounded theory research includes document analysis and semi-structured interviews conducted in
2013/14 with patients, health care providers, administrators and policy makers in several communities in Nunavut.
Thirty five informants in total participated in the study. Interviews were audiotaped, transcribed and analyzed with
qualitative data analysis software for internal consistency and emerging themes.
Results: Four distinct themes emerge from the research that have the potential to impact patient care and which
may provide direction for future policy development: 1) tensions between national versus territorial financial
responsibilities influence health provider decisions that may affect patient care, 2) significant human resources are
utilized in Community Health Centres to perform distribution duties associated with retail pharmacy medications,
3) large quantities of unclaimed prescription medications are suggestive of significant financial losses, suboptimal
patient care and low adherence rates, and 4) the absence of a clear policy and oversight for some controlled
substances, such as narcotics, leaves communities at risk for potential illegal procurement or abuse.
Conclusions: Addressing these issues in future policy development may result in system-wide economic benefits,
improved patient care and adherence, and reduced risk to communities. The interview informants who participated
in this research are best positioned to identify issues in need of attention and will benefit the most from policy
development to address their concerns.
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Profile of Nunavut
Stark contrasts are commonplace in the Arctic, where
light and land, and tradition and modernity mix to cre-
ate unique landscapes. The Arctic territory of Nunavut
is the largest, least populated and newest territory in
Canada, created from negotiations between the federal
government and the Aboriginal Inuit inhabitants of the
region in 1999; as such, 85 % of the population of
Nunavut are Inuit [1]. In contrast to Canada’s high
income and development measures, Nunavut demon-
strates substantially deficient indicators for health and
social and economic development. Nunavut’s epidemio-
logical profile includes disproportionately high levels of
many infectious and chronic diseases, as well as high
age-standardized mortality rates (603 in Nunavut versus
259 in Canada, per 100,000), suicide rates (56.9 in
Nunavut versus 10.4 in Canada, per 100,000) and infant
mortality rates (16.1 in Nunavut versus 5.1 in Canada,
per 1,000 live births) [2]. Life expectancy at birth differ-
entials between Nunavut and the rest of Canada are
seven years for women (76 years versus 83 years,
respectively) and nine years for men (69 years versus
78 years, respectively) [3]. Nunavut is also affected by
social issues such as poverty (the Nunavut average
household income is 10 % lower than the Canadian
average while household food expenditures are three
times the national average), unemployment (46.2 %
employment rate for working-age Inuit), food insecurity
(>70 % of households in Nunavut versus 9 % in
Canada), and low educational attainment (27.5 % high
school graduation rate from 1999 to 2008) [4]. Add-
itionally, high birth rates (2.97 children per woman versus
1.61 per woman for Canada in 2011) and overcrowded
housing (52.7 % live in crowded housing versus 3 % in the
rest of Canada) have significant impacts on health measures
and service needs [5, 6]. The Community Well-Being
Index (CWB) is a composite measure developed by the
Canadian Department of Indian and Northern Affairs,
which considers income, education, housing and labour-
force participation. In the Canadian northern territories,
the average CWB score for Aboriginal communities is
62.0, whereas for the rest of Canada the average CWB
score is 74.2 [3].
Health care in Nunavut is delivered in Community
Health Centres (CHCs) through a nurse-led primary care
delivery model with services being provided predo-
minantly by community health nurses (CHNs); the vast
majority of CHNs are non-Inuit originally from the south
[7]. The territory of Nunavut is divided administratively
into three regions: the Kivalliq in the southwest, the
Kitikmeot in the northwest, and the Qikiqtaaluk in the
east. The two western regions each have a Regional Health
Centre with limited in-patient capacity and extendeddiagnostic testing services (Rankin Inlet in the Kivalliq
and Cambridge Bay in the Kitikmeot). The territorial hos-
pital (Qikiqtani General Hospital) is located in the capital
of Iqaluit in the Qikiqtaaluk. Each of the remaining 22
communities is serviced by a CHC. Regional Health
Centres are distribution hubs for CHC medications, with
Qikiqtani General Hospital serving centralized ordering
and administration roles. At the CHCs, medications are
compounded and/or dispensed by health providers from
bulk containers into smaller amounts for individual pa-
tients as required. For prescribed medications that are not
provided by the CHCs, there are five retail pharmacies
within the territory: two in Iqaluit, two in Rankin Inlet
and one in Cambridge Bay. In communities without a re-
tail pharmacy, all prescribed medications are dispensed by
the closest regional retail pharmacy, flown into the com-
munity and delivered directly to the CHC for distribution
to community members.
This disparity, of an underdeveloped territory situated
within a nation enjoying high development indicators
more generally, creates a unique contrasting backdrop for
pharmaceutical service provisions. Provinces and terri-
tories are responsible for the provision of health services
in accordance with Canada’s publicly funded universal
health care program. The Government of Nunavut (GN)
funds primary and hospital care and inpatient pharmaceu-
ticals in accordance with the GN Drug Formulary Manual.
These pharmaceuticals (referred to as wardstock) are
defined as those that are used “at the time of care in a
health centre, hospital or public health unit, as well as
may be provided in a small supply to treat patients for a
short period after the patient returns home” [8]. Canada’s
universal health care program does not extend to out-
patient prescription pharmaceuticals or over the counter
(OTC) medications. However, as the majority of the popu-
lation of Nunavut are Inuit, they are beneficiaries of the
Non-Insured Health Benefits (NIHB) Program for First
Nations and Inuit. These benefits encompass many health-
related goods and services including 100 % coverage for
most outpatient prescription pharmaceuticals and many
OTCs not covered by the GN; these medications are
dispensed from retail pharmacies [9]. This broad sweeping
medical coverage is the result of historical treaties signed
between Aboriginal groups and the Canadian federal gov-
ernment in the 1870s which included references to a “medi-
cine chest” clause agreeing to provide medical care and
medicines to the Aboriginal peoples who had signed the
treaties [10].Financial expenditures
Federal funding for the NIHB program is allocated from
the First Nations and Inuit Health Branch (FNIHB), as
well as from supplementary Parliamentary funding
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NIHB program registered 926,044 First Nations and
Inuit clients in 2013 with a total budget in 2012/13 of
$1.104 billion. Of total NIHB registered clients, 42,911
(4.6 %) were Inuit and pharmacy costs represented the
largest proportion (41.9 %) of total expenditures at
$462.7 million [11]. National level challenges to control
pharmaceutical expenses include issues such as an aging
population and increased reliance on pharmaceuticals
[11]. Research indicates that due to higher levels of
chronic disease, older individuals are prescribed more
pharmaceuticals at higher costs than younger individuals
[12]. Challenges specific to the NIHB program sustain-
ability include population growth rates in its client base
that are double that of the national average (Nunavut
has the highest fertility rate in the country), and provid-
ing service to clients in remote and small communities
[11]. The remoteness of Arctic communities provides
unique challenges for pharmacy expenditure manage-
ment (e.g. control of inventory levels) and oversight.
The NIHB Annual Report for 2012/13 indicates that
pharmacy utilization rates - expressed as clients receiv-
ing at least one pharmacy benefit throughout the year as
a proportion of the total number of eligible clients - are
substantially lower in Nunavut (~45 %) than national
NIHB averages (~62 %). In fact, Nunavut has the lowest
utilization rates of all NIHB regions. This relatively low
utilization rate, combined with a younger population
than in other regions, is also reflected in the lowest per
capita expenditures of all NIHB regions: $336 per
capita in Nunavut compared to the NIHB average of
$483 per capita. Average 2012/13 pharmacy expendi-
tures in Nunavut were $718 per client, slightly lower
than the NIHB national average of $750 per client.
Total NIHB pharmacy expenditures in Nunavut were
approximately $10.7 million in 2012/13. These costs
increased 157 % between 2003 and 2013 (Table 1) [11].
Territorial funding for the GN Pharmacy Program is
through territorial budget allocation and supplemental
funding as required. The Territorial Pharmacy Program
focuses primarily on the acquisition and distribution of
pharmaceuticals to all territorial health facilities; how-
ever, it also funds vaccines, blood services, contracted
services and travel and transportation costs for leaveTable 1 Federal non-insured health benefits (NIHB) and territorial Gov
of Canadian dollars), in Nunavut, 2003–2013
NIHB annual pharmacy expenditures in Nunavut
2003/04 2004/05 2005/06 2006/07 2007/08
4.150 4.734 4.902 5.526 6.579
GN annual pharmacy expenditures in Nunavut
2003/04 2004/05 2005/06 2006/07 2007/08
Data unavailablereplacement positions [13]. Vaccines in the territory
comprise 48 % of total drug costs due to the high popu-
lation growth rates (most vaccines are administered to
children), and the availability of Synagis® (Palivizumab), a
vaccine given to high risk infants to prevent Respiratory
Syncytial Virus (RSV) infections. Synagis® comprises
45 % of total vaccine expenditures or 21.6 % of total
pharmaceutical expenditures [13]. Total GN pharmacy ex-
penditures in 2012/13 were approximately $2.8 million.
These costs increased by 7.7 % between 2010 and 2013
(Table 1). Similarly, NIHB costs increased by 2.8 % during
the same time period.
The overlay of social and economic marginalization
with no-charge pharmaceuticals creates a landscape of
both advantages and challenges requiring creative and
adaptive policies and procedures for pharmaceutical
service delivery. Ultimately, this landscape provides an
important opportunity to provide pharmaceuticals where
they otherwise might not be accessible, and to supple-
ment health care services to improve health outcomes
for the people of Nunavut.
Pharmaceutical policy development
The mandate of policy is to regulate and govern the set of
principles that guide decision making however, responsive
health policy development is best facilitated through the
routine input from front line service users and stake-
holders [14]. Crucial information on the successes and
shortcomings of policy application, or how it works in
real life, must be available for adaptive and responsive
policy development. There is an absence of published
academic or governmental research regarding pharma-
ceutical practice in Nunavut despite considerable federal
and territorial expenditures on pharmaceuticals and
their importance with respect to health care delivery.
Pharmaceutical health care for the people of Nunavut
(referred to as Nunavummiut) is influenced by distinct
Canadian federal and Nunavut territorial payment responsi-
bilities for pharmaceuticals, as well as challenges in service
provision to remote Arctic communities that are often
affected by staffing shortages and isolation due to weather-
related access issues. These factors introduce tensions into
the acquisition, management and distribution processes
which ultimately impact health care decisions. Thisernment of Nunavut (GN) pharmaceutical expenditures (in millions
2008/09 2009/10 2010/11 2011/12 2012/13
7.084 8.237 10.399 10.894 10.690
2008/09 2009/10 2010/11 2011/12 2012/13
2.6 2.4 2.8
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patients, health care providers and policy makers in sev-
eral communities in Nunavut to consider the research
question of how existing pharmaceutical administration
and distribution policies and practices in Nunavut impact
patient care.
Methods
This grounded theory community-based research and
fieldwork was conducted between 2012 and 2014. The GN
and community of Arviat invited research on pharmaceu-
ticals due to concerns within the territory and specifically
within the community as to policies and practices affecting
patient care. Research planning and fieldwork was guided
through consultation and assistance with the Qaujigiartiit
Health Research Centre in Arviat and research associates
who were long-term residents of Arviat. The topics and
questions on the interview guide originated from commu-
nity consultation during fieldwork in 2013 which were
then edited and approved by the community prior to sub-
mission and further review by the Nunavut Research Insti-
tute for licensing approval. The diverse interests and
concerns evident within the community and territory sug-
gested that exploration of several issues was required.
Therefore, this research follows a grounded theory frame-
work and was designed so as to allow for the development
of themes to emerge from the research itself [15].
Research methods include document analysis and semi-
structured interviews. Document analysis includes review
of federal and territorial policy documents and financial
reports. Interviews were conducted in May 2014 with 35
participants in total, including residents/patients and health
care providers from Arviat, health care providers and
administrators from the Regional Health Centre and
Qikiqtani General Hospital in Rankin Inlet and Iqaluit, and
key policy makers in Iqaluit and Ottawa. Participants in-
cluded CHC administrators, physicians, front counter staff,
translators, CHNs working in various health care facilities,
pharmacists and pharmacy technicians, community health
representatives, and members of the Nunavut Pharmacy
and Therapeutics Committee. Some participants provided
interview responses based on multiple roles (e.g. as both
health care providers and community residents). Partici-
pants were recruited for interviews through several
methods including convenience sampling through informa-
tion posted in several public locations in Arviat, local radio
promotion inviting participation, snowball sampling, and
purposive sampling for key informants. Interviews were
conducted in private rooms, lasted a minimum of one hour
in length and were audio recorded and transcribed for
analysis. Research protocols received institutional approval
through the University of Toronto’s Office of Research
Ethics (Protocol # 28248) and were licensed through the
Nunavut Research Institute (License # 01 033 13 N-M).This research was designed to explore how existing
pharmaceutical administration and distribution policies and
practices impact patient care. In consideration of these re-
search goals, interviews included open-ended questions re-
garding participants’ personal and professional (if applicable)
experiences with pharmacy services (e.g. “Tell me about
your experiences with medications”). Interview guides were
developed with community, territorial and institutional as-
sistance and questions were tailored for specific interview
participant roles. For example, health providers were
asked about the administration of their daily work
while community members were asked about their
personal experiences with medication acquisition and
availability. Special care was taken to ensure language
was appropriate to participant roles and simplified to
reflect common language terms. Specifically, patient
informed consent forms and questions were developed
with institutional guidance from departmental re-
searchers in populations with similar considerations of
low educational and literacy levels; in Nunavut this
can occur in both English and Inuktitut. Among Abo-
riginal adults in Nunavut, only 55 % have completed edu-
cation above an elementary level [3]. Interview materials
were translated into Inuktitut and participants were of-
fered either English or Inuktitut documentation. Inter-
preters were made available on request for interviews.
None of the participants elected for the use of an inter-
preter, and few selected the Inuktitut documentation.
Verification and clarification was sought through iterative
questioning until internally consistent understandings
were observed. For example, distribution was explored
throughout the supply chain and patient-provider encoun-
ters were verified from multiple informants on both sides
of those transactions whenever possible.
QSR-NVIVO v10.2 [16] software was used to code and
analyze data. The coding strategy developed for data analysis
included using nodes to identify themes within the data and
attributes to identify demographic information (i.e. ethnicity,
role and community affiliation) from participants. The
conceptual framework was informed by open coding, with
emergent tree nodes outlining broad themes and child nodes
allowing for more in-depth interrogation of the data. Queries
on key words and themes were used to analyze the data and
saturation was established when supporting evidence for
findings was collected and found to be consistent from all
participants within similar roles or with similar attributes.
Results
Several key issues are consistently discussed among research
participants and supported by document analysis. These is-
sues involve: 1) the distinct NIHB and GN financial respon-
sibilities for pharmaceuticals and their impact on health
provider decisions for medication sourcing; 2) the resource
requirements from CHCs to distribute retail pharmacy
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challenges associated with the return and disposal of un-
claimed and expired medications.
NIHB and GN financial responsibilities and medication
sourcing
In theory, Inuk residents of Nunavut should be beneficiar-
ies of some of the most complete medical coverage in
Canada. While 10 % of Canadians report cost-related non-
adherence to prescription medications [17], and 14 to 39 %
(depending on province) of Canadians are uninsured for
prescription medications [18], all beneficiaries of the Non-
Insured Health Benefits program receive coverage for most
prescription medications and many OTC medications such
as antihistamines and acetaminophen [9]. In practice how-
ever, both the NIHB and the GN have been the subject of
serious criticism stemming from federal audits of their ad-
ministration and accountability for their respective pro-
gramming, including pharmaceutical health care. The
NIHB program has been criticized for serious oversights in
monitoring of drug utilization and poor management and
control of program expenditures, in particular the manage-
ment of pharmacy benefits [19]. The GN has similarly been
notified of serious concerns in regards to its financial man-
agement practices, lack of budget planning and consistent
overspending, although notably, these issues were primarily
attributed to the significant number of staffing vacancies
and recognized difficulties in recruiting and retaining em-
ployees in the territory [20]. An example of the repercus-
sions of the lack of GN financial management was the
termination of a business relationship between the GN and
a specialized pharmaceutical supplier due to vendor dissat-
isfaction. Both the NIHB and GN have recognized fiscal
management issues that impact policy control and ac-
countability, however lack of oversight may also hinder the
examination of procedural discrepancies that are occurring
in health care settings. These management issues affect ad-
ministration and delivery of services throughout the terri-
tory and have the potential to impact patient care.
Policy
Prescribing policies dictate that pharmaceuticals that do
not meet the criteria for inpatient medications (including
OTC) are to be prescribed and acquired through retail
pharmacies. Remote communities often do not have full
time health care providers with prescribing privileges such
as nurse practitioners (NPs) and physicians in the commu-
nity. Compared with Canadians overall, Aboriginal inhabi-
tants in the territories are significantly less likely to have
had contact with a General Practitioner or any other med-
ical doctor in the past 12 months (58.8 % versus 78.7 %),
and are significantly more likely to have had contact with
a nurse than the average Canadian (49.0 % versus 9.8 %,
respectively) [21]. Given that the majority of care inremote communities is delivered by nurses, Nunavut’s ex-
tended scope of practice allows CHNs and midwives to
dispense many medications from wardstock [22]. In situa-
tions when a class of medication is unable to be dispensed
by a CHN, prescriptions can only be obtained by commu-
nicating with the remote doctor on call.
Practice
Divided federal and territorial financial responsibilities for
pharmaceuticals create considerable tensions within the
system between the NIHB and the GN. Health provider
research participants discussed many factors influencing
their decisions regarding medication sourcing (NIHB
prescription or GN wardstock) including: pressures to
shift expenses to maximize NIHB benefits, availability of a
retail pharmacy in the community, weather, access to a
prescribing health provider and staffing shortages.
Within CHCs, health providers are actively encour-
aged to minimize use of wardstock and maximize the
use of NIHB benefits by writing prescriptions from retail
pharmacies. One informant, a health provider in a com-
munity with a retail pharmacy, discussed a patient who
had attended the CHC during regular business hours
and was in need of a prescribed medication that was
available in the CHC dispensary.
“We have bottles of wardstock and the CHNs are
allowed to dispense…[but] we would give them a
prescription to go to the pharmacy…[administration]
does not want us to [give the patient even a starter
dose] because of budget…five years ago, they’d have
gotten their meds from here”.
In remote communities without retail pharmacies,
weather delays and retail pharmacy dispensing times can
delay pharmacy deliveries by anywhere from two to ten
days. These delays in many cases would significantly
impact patient care, and for this reason more medica-
tions are dispensed directly from wardstock and fewer
prescriptions are written from retail pharmacies that
would be expensed to the NIHB.
When a health care provider with prescribing privileges
is unavailable within the community, CHNs are more likely
to dispense a full course of medicine than to attempt to
contact a prescriber outside the community for autho-
rization, or to wait until a prescriber is available in person.
Even in situations when a prescriber is within the commu-
nity, it has been noted that understaffing (a common issue
in the north) and/or high patient loads can cause CHNs to
dispense medications from wardstock rather than seek out
providers for prescription authorizations. A health care
provider interviewed, referring to the GN’s Formulary Drug
Treatment Codes categorizing medications which can be
only initiated by a physician as “code B” medications,
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Bother the Doctor”, while “code D” medications for which
one dose may be dispensed by a CHN are referred to as “D
is for Do It Yourself”. Health providers in remote locations
are necessarily called upon to practice more independently
and medication sourcing is but one of these areas of
practice.Distribution of retail pharmacy prescriptions through
community health centres
In the majority of Nunavut communities, primary care is
delivery by nurses with physicians only visiting sporadic-
ally based on rotating schedules and weather-related ac-
cessibility. Staff turnover for remote nursing is recognized
as a serious challenge, with vacancy rates between 37 and
57 % across the regions in Nunavut [23]. These nursing
shortages have been noted to result in an increased reli-
ance on casual nursing staff with decreased familiarity
with Inuit culture, a shift from primary health care to
more emergent acute and chronic care, and increased
stress levels on nurses leading to decreased job satisfac-
tion, and burnout [23, 24]. Nurses practicing under an ex-
tended scope of practice take on duties that southern
nurses in more urban centres are not asked to perform,
with routine staffing shortages further exacerbating the
situation. Health care informants indicate that they are
often called upon to take on increasing levels of adminis-
trative work, such as the distribution of retail pharmacy
prescriptions, which take time away from patient care.Policy
In communities without retail pharmacies, many of the
administrative roles of pharmacists (i.e. stocking, distri-
bution of medications to patients and patient counsel-
ling), are performed by CHCs. When medications from
retail pharmacies arrive at the CHC, staff are required to
verify shipping records and then provide a list to admin-
istrative staff for patient notification. Front counter staff
then make attempts to contact the patient (generally by
phone) to inform them that their medication has arrived.
Unpacked medications are to be shelved in an organized
manner (alphabetically by packaging type) in the CHC
dispensary to await patient pickup.
Many chronic medications are prescribed with auto-
matic refills, indicating that retail pharmacies send out
one month supplies of medication at regular intervals
without further instruction required until the prescrip-
tion expires. There is currently no system in place to
inform the retail pharmacy if the current prescription
has been picked up, therefore pharmacists proceed with
the assumption that the next month’s supply of medica-
tion is required, even if a previously unclaimed prescrip-
tion is still shelved in the CHC dispensary.Practice
When understaffing and high patient loads occur, duties
associated with retail pharmacy deliveries may be de-
prioritized. Many health care provider informants voice
displeasure and frustration with the additional adminis-
trative burdens of these deliveries, which they see as tak-
ing time away from patient care. As one health provider
informant stated,
“there’s boxes and boxes and boxes, I’m talking
hundreds of prescriptions a week, that are filtering
through this Health Centre …if I had to sit every day
and figure out people’s phone numbers, most people
have no phones, some people are nomadic, they’re
moving from house to house, it’s very difficult to track
them down to say ‘hey, your medications are here’.”
Community participants speak of not receiving notifi-
cation that their prescriptions have arrived and visiting
the CHC several times to make enquiries, sometimes to
discover that their medications had arrived a week or
more earlier. As two patient informants voiced,
“we’ve had prescriptions sit at the Health Centre, for a
week or two, longer than they should, and we were
waiting…so they’re in the community, and they haven’t
called us. They’ll say ‘this came in last week; we didn’t
know you were waiting for it’.”
Many health care provider participants note that there
are a large number of patients who never retrieve these
medications. While lack of awareness among patients that
their medications have arrived is one possible explanation,
health provider informants suggested several other possi-
bilities including: lack of understanding for the rationale
for the medication, denial of their medical diagnosis or the
severity of potential outcomes of non-adherence and dis-
trust of medications. As the vast majority of Nunavummiut
speak Inuktitut as their first language and few health care
providers are fluent, language challenges may also contrib-
ute to misunderstandings [25]. Family pressure can also
impact adherence, for example a health care provider in-
formant described an incident when they asked a patient
diagnosed with severe depression if they were taking their
medications, and they responded,
“my grandmother said that I am not mentally ill and
‘you’re not taking that medicine’.”
Informants suggest another possible factor might be
the lack of understanding among many Inuit as to the
high cost of medications. Inuit are life-long recipients of
pharmaceuticals provided with no patient co-pay, in-
cluding such OTC medications as acetaminophen and
Fig. 1 Racks of convenience packaging (i.e. blister packs) of
medications awaiting patient pickup in the Community Health
Centre (CHC) dispensary. Storage and organization of these large
volumes of medication is a challenge. (Photograph by Sandra
Romain)
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retail pharmacies, there is no cash value printed on the
receipt. Informants suggested that an understanding of
the financial value of the medications that are being
prescribed might influence adherence by Inuit patients.
As one health provider informant, with over 7 years of
service in Nunavut discussed,
“with the HPV vaccine, we were having really low impact
and one of the conversations that I started to have was
‘do you realize that people have to pay for it and that
and [we] are now offering it for free?’, and then people
were kind of like ‘oh’, like it kinda got their attention.
Not that it’s going to keep your daughter from having
cancer…but when it’s free! [referring to medication]…
maybe if they don’t see the value in it, they don’t bother
or they throw it away or something like that”.
Through what is likely a combination of these factors,
virtually all participants consistently note that many
retail pharmacy medications are not getting to, or being
used by, the intended patient.
Unclaimed medications were observed in the CHC
dispensary in overflowing boxes and shelving units
(Figs. 1, 2 and 3). Several patients were observed to have
multiple prescriptions dating back three of four months.
Many health providers voice frustration with this issue
and the economic wastage incurred. As one health care
provider informant explained,
“The problem is, when a physician writes a
prescription, commonly three, four, six refills may go
on that prescription…sometimes we get a backlog…
the other day I noticed that we had a four month
supply of a medication for a child who I knew was
no longer even in the community. This is a
problem, it is a wastage of medication, medications
are having to be destroyed, at least once a month
there is a box full of medications, for various
reasons…hundreds of thousands of dollars worth in
loss…I calculated there not too long ago that one
certain load of medication came in from a
household and there was nothing short of about 12
to 15 thousand dollars worth of medication. This is
a problem.”
Although there is some confusion as to where this
notification chain breaks down, the effects of this
disorganization can negatively impact patient care
through loss of trust in the CHC, as two community
informants indicated:
I1: in the bubble packs…a lot of people who have
chronic illness have bubble packs, right? They are
Fig. 2 Bundles of medications in convenience packaging (i.e. blister
packs) awaiting patient pick-up in the Community Health Centre
(CHC) dispensary. Each convenience pack contains medications for
one week. Many medications arrive in communities dispensed with
sufficient medication for one month. This is shown in the bundles of
four blister packs. (Photograph by Sandra Romain)
Fig. 3 A box of unclaimed retail pharmacy medications, the majority in
convenience packaging (i.e. blister packs), awaiting return to the Regional
Health Centre for disposal through incineration. Some informants indicated
that medications might be returned in medical sharps containers (seen
bottom right) to facilitate disposal. (Photograph by Sandra Romain)
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milligram, they’ll be on it for a long time and not
understand why when ‘the doctor said I should be
off it by now and I’m still on it’
SR: So the doctor is saying “we’re going to discontinue on
this”?
I1: oh, yeah
SR: but the next blister pack that arrives…
I1: yes
SR:still has the pills in it?
I1: yep
SR: Now what does the person do? Just takes it?
I1: usually
SR: just assumes, “oh, I guess I misunderstood?”
I1: yep
I2: or they start to mistrust the Health Centre and they
stop taking all their pills all together
I1: oh, yeah - that’s a big one
Many health providers voice the most frustration with
the lack of an effective mechanism to stop retail phar-
macies from filling repeat prescriptions when the patient
has not yet picked up the previous prescription. This is
stated to be the greatest source of multiple unclaimed
prescriptions for the same individual being stored in the
dispensary. Several practices have been used to minimize
repeat unclaimed prescriptions, although none are imple-
mented broadly across the territory or with proven results.
One health provider informant indicates that they now
issue repeat prescriptions with a written notation of “as
requested by patient”, to necessitate a patient initiated
refill. One CHC in the Kivalliq provides a phone at the
front desk to actively encourage patient calls to the phar-
macy at the time of pick-up so that the patient can request
their next month’s prescription be filled. A key pharmacy
informant mentions a corresponding increase in patient
calls from this community without solicitation, although
the informant is unaware as to the reason why this com-
munity had noticeably more calls than others. One health
provider informant is familiar with a double label system
used in other jurisdictions (e.g. Labrador), whereby the
retail pharmacy prints two labels for each retail pharmacy
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one label is removed, affixed to a reorder sheet and faxed
back to the pharmacist to inform them that the patient
has received the medication and they are authorized to
refill the following month’s prescription. While some health
provider informants are enthusiastic about these various
interventions, others voice concerns about the labour in-
tensive administrative process and increasing responsibility
for medication management on the part of CHC staff.
The substantial and sustained requirements of the
already taxed CHCs and CHNs to organize, store and
distribute retail pharmacy medications likely contributes
to the large quantity of unclaimed medications which
are indicative of patient non-adherence and suboptimal
pharmacotherapy.
Return and disposal of unclaimed and expired
medications
Improper pharmaceutical waste management can have
significant health, criminal and environmental impacts.
In relation to health and safety, most medications are
still considered safe beyond their expiration dates, how-
ever some (e.g. nitroglycerin, insulin, liquid antibiotics,
epinephrine pens) lose efficacy and given the emergent
need for these drugs during life threatening situations,
potency is mandatory [26]. Criminally, recreational mis-
use of illegally obtained pharmaceuticals, often from
family medicine cabinets or friends, is a growing trend
in Canada resulting in increases in theft and fraud as
well as health impacts such as overdose deaths, suicides
and emergency care costs [27, 28]. Environmentally,
pharmacologically active substances have been detected in
surface and ground water at levels rivalling some pesticides
[29]. This is especially problematic given the environmental
sensitivity of arctic ecosystems and the heavy reliance on
subsistence hunting of both land and sea mammals.
Policy
Some medications purchased for wardstock by the GN
may expire prior to dispensing in the CHCs. As part of
regularly scheduled inventory within CHC dispensaries,
wardstock is to be shelved in consideration of expiration
dates (i.e. newer stock at the back) and any expired
medications are to be removed to ensure patient safety.
Some expired medications may also be eligible for reim-
bursements from manufacturers or distributors. According
to a key pharmacy informant, some injectable or intraven-
ous drugs may be eligible for reimbursements of as much
as $2,700 for a single expired dose.
Expired wardstock medications that are ineligible for
reimbursement and unclaimed retail pharmacy medica-
tions require environmentally safe disposal and may also
be subject to control protocols (e.g. narcotics). The
proper disposal of pharmaceuticals in Nunavut isgoverned by the GN Narcotic and Controlled Drugs Pol-
icy (revised edition released Fall 2014) which regulates
the “acquisition, storage, prescribing, administration,
record keeping and disposal of narcotic and controlled
drugs” as well as the responsibilities of authorized health
care providers who work with these substances, and by
the federal Controlled Drugs and Substances Act [30].
Controlled substances entering the community are
closely monitored with pill counts, sealed shipping enve-
lopes and double signatures. However, if these medica-
tions are unclaimed or expired, only GN wardstock
narcotic and controlled substances are subject to the
same procedures in reverse when leaving the commu-
nity; retail pharmacy medications are subject only to
routine disposal. Unclaimed retail pharmacy medica-
tions and expired wardstock are sent to Regional
Health Centres for incineration or (less frequently) to
retail pharmacies for waste management.
Unclaimed retail pharmacy medications that are not
picked up may also be eligible for reversal of NIHB expenses
through a procedure to reabsorb costs while continuing to
remunerate pharmacists for their dispensing fees. Retail
pharmacies have varied requirements for accepting these
returns. One key pharmacy informant indicates that these
reversals are only possible for unclaimed medications that
would have been dispensed directly from the retail pharma-
cies (i.e. to in-town clients) as they are able to confirm the
environmental conditions of medication storage, as well as
ensure that the medication has been kept in a secure loca-
tion and has not been subject to tampering. Unclaimed
medication reversals are not accepted by some retail phar-
macies when medications are dispensed for use in remote
communities. Yet another key pharmacy informant indicates
that the supply chain from pharmacy to CHC and back was
sufficiently controlled to allow for a reversal, as it was secure
enough for narcotic and controlled substances protocols.
When unclaimed retail pharmacy medications are unable to
be returned to retail pharmacies, CHCs are instructed to
send them to Regional Health Centres with expired GN
wardstock for incineration.
Practice
In speaking to many community member participants
about what they do with their personal unused medica-
tions, most indicate that they throw them in the garbage.
In recognition of this issue and as confirmation of its
significance, one health worker informant describes a
door-to-door “spring clean up” program that was orga-
nized for collecting household medications; this initiative
collects several large garbage bags annually requiring the
use of a pickup truck due to weight. These findings indi-
cate that there are likely large quantities of unused med-
ications in community homes that would benefit from
assisted disposal programs.
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claimed medications require frequent disposal services.
Participants provide varied and ambiguous responses to
enquiries regarding this process, alternatively indicating
that medications are shipped in sealed cardboard boxes
or that they are deposited individually into medical
sharps containers and sealed before shipment (Fig. 3).
This latter process requires the time consuming process
of removing individual medications from the many
unclaimed blister packs. Many interview participants de-
scribe the time consuming and necessarily deprioritized
efforts to routinely return the large quantities of medica-
tions for destruction. Time lapses between shipments
are estimated to be between one and three months in
duration, depending on staffing and storage capacity.
Several interview participants at both the provider and
administrative levels discuss the practice of the transfer
of retail pharmacy medications into wardstock inventory.
Participants explain this practice as being done through
either front-end or back-end restocking. If a CHC dis-
pensary does not have stock of a medication that is
needed immediately and one is available in the storage
units holding retail pharmacy medications that have not
yet been picked up, they might dispense the retail phar-
macy medication to the patient in immediate need. One
patient informant described their experience,
“we’ve gotten something out of the dispensary and it
will have somebody else’s label already on it from
[retail pharmacy name]…so they’ve taken a labeled
drug from [retail pharmacy name] and put them in
the dispensary and relabeled it to give it to us.”
This front-end substitution may leave the patient for
whom the medication was specifically intended without
the medication, but informants note that either the
medication is replaced with GN wardstock when it
arrives or that more frequently, the medication is taken
from the extensive supply of unclaimed retail pharmacy
medications that would eventually need to be inciner-
ated. This practice is stated to be extensive enough as to
reduce budgetary requirements for CHC inventory. As
one health administrator informant states,
“If I had twenty patients that I was getting prescriptions
in monthly that they never pick up, and I put them in
my stock, and use them to dispense, I’m at zero
budget…I’ve been in communities where they are
doing it”.
An alternative form of this medication substitution is
the replacement of medications already dispensed from
wardstock with retail pharmacy medications. This back-
end substitution is used when a medication is dispensedfrom wardstock that might otherwise be prescribed from
a retail pharmacist, but that due to timely need (e.g.
impending weather) is dispensed directly from the CHC.
The prescription for the patient is then sent to the retail
pharmacy and when the medication arrives, it is used to
replace the GN wardstock that has already been previ-
ously dispensed. Although these practices have significant
budgetary and possibly legal implications, the health pro-
vider informants interviewed are most concerned with
patient-centred care and are focusing on the urgency to fill
an immediate patient need for medications that could take
days or weeks to arrive.
Practices at this time do not track or inventory the
destruction medications, including retail pharmacy con-
trolled substances such as narcotics. This lack of oversight
could foreseeably result in the unlawful removal of con-
trolled substances by unauthorized individuals. Health
provider informants at several levels are concerned that
although unclaimed retail pharmacy narcotics are kept in
a secure, separate location from other non-controlled
medications in the CHC dispensary, that there are few
procedures in place to ensure the unclaimed narcotics are
destroyed lawfully and appropriately. While the protocol
for the destruction of expired GN wardstock controlled
substances is compliant with the Controlled Drugs and
Substances Act, several key informants indicate that there
is considerable concern and debate among stakeholders as
to the legal and financial responsibility for the disposal of
retail pharmacy narcotic and controlled substances. At the
centre of the controversy is confusion about ownership
and authority over a prescribed medication intended for
an individual who has never taken possession. However,
the lack of current oversight in regards to their destruc-
tion presents a significant risk for the “disappearance” (i.e.
unlawful removal) of these medications. These issues are
currently under consideration by the GN Pharmacy and
Therapeutics Committee in consultation with the NIHB
and legal counsel to ensure the development of a policy to
address this issue.
Discussion
A number of key themes emerge from the interviews
conducted for this research: 1) the tensions between
NIHB and GN financial responsibilities influence the
decisions of health providers and may affect patient care,
2) significant human resources are utilized in Com-
munity Health Centres to perform distribution duties
associated with retail pharmacy medications; 3) large
quantities of unclaimed prescription medications are
suggestive of significant financial losses, suboptimal pa-
tient care and lower adherence rates; and, 4) the absence
of a clear policy and oversight of some controlled sub-
stances, such as narcotics, leaves communities at risk for
potential illegal procurement or abuse.
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pharmaceuticals
As the NIHB is a federally administered program respon-
sible for multiple jurisdictions, Nunavut may be subject to
less direct review of expenditures compared to other juris-
dictions due to its low pharmacy utilization rates, lowest
per capita expenditures and lowest overall pharmaceutical
costs. These low figures, combined with past claims of
program mismanagement and lack of oversight may be
contributing factors in some of the practices identified by
research participants leading to unnecessary repeat pre-
scriptions and unclaimed medications. Concurrently, due
to the GN’s recognized staffing issues and financial mis-
management in the Department of Health and Social
Services, concern regarding the oversight of pharmaceutical
expenses may be reasonable.
As CHC administrators are evaluated on their ability
to balance their budgets inclusive of wardstock phar-
maceutical costs, this may contribute to the practice of
inventory transfer from NIHB medications to GN ward-
stock when retail pharmacy medications are available
and unclaimed. Additionally, frustration with the losses
associated with quality medications going unclaimed and
heading for incineration, and/or with insufficient inven-
tory levels to reflect isolated communities may influence
health provider decisions to use retail pharmacy medica-
tions for CHC patient care. Systemic policy modifications
might reduce the necessity to transfer stock from the
NIHB to the GN through increased efficiency in inventory
management systems.
Decision making for front line health providers is com-
plex and often involves many considerations that are
beyond merely following policy guidelines. Ultimately what
is most prominent in interviews is decision making that is
patient-centred above other considerations. However, in-
creased situational pressures (such as isolation and staffing
shortages) on CHNs to independently dispense medications
from GN wardstock may reduce pharmacy industry recom-
mended independent double-checks and increase the
potential for dispensing errors. Policy development that
recognizes the complexity of the medication sourcing
decision-making process may support health providers in
their focus on patient care.Theme two: Pharmacy duties of Community
Health Centres
Research participants working in CHCs repeatedly voice
frustration and displeasure for the duties and responsi-
bilities associated with the distribution of retail phar-
macy medications. Many felt that the role and associated
tasks of a pharmacist were being forced on the CHC
when understaffing was a common concern. Their in-
ability to perform the time consuming task of notifyingpatients that their medications were available for pickup
is a source of irritation and frustration. Informants
recognize that patient non-adherence is likely impacted
by an inability for patients to pick up their medications,
but also impeded by staffing capacity to notify patients
and organize and distribute medications. None of the
participants suggest that they are “above” the task, but
identify it as an impediment to seeing patients and their
many other duties.
Many patient participants also voice frustration with
the deprioritized notification of medication arrivals or
loss of their medications due to the challenges of storing
and organizing large volumes of patient-specific medica-
tions in the CHC dispensary. Several interview partici-
pants in Arviat strongly suggest that a retail pharmacy is
needed in the community and that the population size
(~3000) supports the investment, identifying that it
would release the CHC from its current responsibilities
for the distribution of prescriptions. Overwhelmingly, all
interview participants – health providers and patients - are
dissatisfied with the current distribution system within
CHCs for prescriptions arriving from retail pharmacies
outside of the community. This issue affects the majority
of communities in Nunavut, as only three of the twenty-
five communities currently have retail pharmacies. Not all
communities have population sizes that would support a
retail pharmacy, however many health care informants ex-
press interest in exploring other options, such as the in-
clusion of a pharmacy technician on staff at CHCs to take
on a distinctly tailored role including specific administra-
tion, inventory and distribution duties.
Theme three: Losses associated with unclaimed
prescriptions
The administrative challenges of CHC distribution prac-
tices are likely reflected in the large number of unclaimed
prescriptions. Unclaimed medications result in significant
loss of human resource capacity through repeat attempts
to contact patients, time taken to package up and return
medications for disposal, return shipping costs and incin-
eration. These unclaimed medications also signify sub-
stantial financial losses as NIHB funded medications are
not being used for patient care.
Retail pharmacy policy that is unreceptive to the return
and NIHB expense reversal of unclaimed medications
may reflect safety concerns, but there is also minimal
financial motivation to reabsorb stock or to rapidly re-
spond to prescription discontinuation requests. While
pharmacies that accept the return of unclaimed medica-
tions are still entitled to claim a dispensing fee from the
NIHB through a special code for this purpose, they are
effectively performing two distinct tasks (i.e. dispensing
and then reabsorbing medications back into stock) and
being reimbursed for only one. Additionally, the pharmacy
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dates and/or if the returned product is resalable.
Several strategies to minimize automatic prescription
repeats are suggested but untested. Further examination
into the efficacy of these different approaches might pro-
vide sufficient evidence to standardize a method to
reduce these losses across the territory. If similar issues
of repeat and unclaimed prescriptions are found in other
jurisdictions nationally, the savings to the NIHB could
be quite substantial.
What is repeated vehemently among many health pro-
vider informants is their disbelief that this long term wast-
age is apparently going unnoticed and that auditing or
regulatory bodies have not identified these losses and found
a way to minimize their occurrence. This lack of oversight
might be better understood in light of the Auditor General’s
Report on the NIHB, and Nunavut’s relatively low per
capita pharmacy utilization rates, however this area of con-
cern would benefit from further examination. Policy devel-
opment that recognizes the limited staffing in CHCs and
the need for enhanced communication with retail pharma-
cies may facilitate medication delivery to patients and reduce
the financial losses attributed to unclaimed medications.
Theme four: Controlled drugs oversight and potential for
illegal procurement
As an associated result of the excessive unclaimed prescrip-
tions, the potential for the illegal procurement of narcotics
and controlled substances is highlighted as a potential
threat to the community. Health provider informants are
genuinely concerned and looking for guidance to minimize
this risk. The absence of policy and oversight on this issue
presents an opportunity for narcotics to be abused or avail-
able for illegal trade. Interviews demonstrated that there is
an urgent need for this risk to be mitigated through a clear
policy that is compliant with the federal Controlled Drugs
and Substances Act. Policy makers are struggling with these
issues currently, to minimize the great risks of narcotics
that can go unaccounted for with little to no notice. This
timely issue poses great risks to communities every day that
a clear policy is not available and consistently administered.
Conclusions
This research identifies several areas of concern which may
prove beneficial in providing direction for future policy
development that best serves the needs of Nunavummiut:
1) NIHB and GN financial responsibilities for pharmaceuti-
cals and their effects on medication sourcing, 2) resource
requirements of CHCs to distribute retail pharmacy me-
dications, 3) human resource, patient adherence and
financial losses associated with unclaimed medications,
and 4) community risks associated with the absence of
clear policy for the disposal of controlled substances. The
financial, health, safety and efficiency issues identified inthis research require consideration through policy develop-
ment that is familiar with the many challenges of service
provision in Nunavut. Demographic factors such as a
young and rapidly growing population combined with geo-
graphical, sociological and environmental challenges affect
the selection and the availability of medications where and
when they are required. The tensions created by the com-
peting NIHB and GN financial responsibilities affect every-
one from the GN policy writers to the Inuit child in need
of an out-of-stock inhaler in a storm-isolated community.
Health providers in remote communities make deci-
sions first and foremost based on patient care, but often
these decisions put their actions in direct conflict with
policy and procedures that may not be reflective of the
realities of stock shortages and dispensing challenges in
a small, remote community. Given that providers are
most aware of both the needs of quality patient care and
the policy restrictions that create challenges in meeting
this demand, future policy development should be con-
sidered that is reflective of this knowledge and mini-
mizes the need for providers to make decisions that may
fall outside of accepted policies and procedures.
Through addressing these identified issues in future pol-
icy development, several benefits may be possible: financial
savings may be realized through minimizing pharmaceut-
ical wastage, community safety may be improved through
the proper administration and disposal of medications in-
cluding controlled substances, and adherence may increase
through consistency, availability and accuracy of medica-
tions. Participants in this research, who live and work in
Nunavut, have been best suited to identify issues in need
of attention, and are also positioned to benefit the most
from policy development which addresses their concerns.
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